The IPO Market in Mid-2026: A Busy and Uneven Season
The U.S. IPO market has been notably active in the first half of 2026, with a wide range of companies across sectors — from energy and biotech to aerospace and mining — completing their public debuts in recent weeks. The returns have been anything but uniform, reflecting both investor enthusiasm in some corners and skepticism in others.
The Headline Deal: SpaceX Goes Public
The single largest event dominating the 2026 IPO calendar is the public offering of SpaceX, which priced on June 11 under the ticker SPCX. With a deal size of $75 billion, it stands as one of the largest IPOs in market history. As of this week, the stock is trading at roughly $161, representing a return of around 19% from its offer price. The scale of the deal dwarfs everything else on the recent pricing calendar and signals significant institutional appetite for high-profile names with long-term growth narratives in the space sector.
A Broad Sweep of Sectors
Beyond SpaceX, the past several weeks have seen offerings across a striking variety of industries, reflecting how broadly companies have chosen to tap public markets this season.
On the energy side, Fervo Energy (FRVO) — a geothermal power company — raised $1.89 billion in a May 12 offering and has since gained about 30% from its IPO price. INNIO (INIO), which raised $2.43 billion in early June, is up nearly 20%. X-Energy (XE), a nuclear energy firm that priced in late April, has had a rougher go, currently trading about 19% below its offer price.
In biotech and pharmaceuticals, results have been sharply split. Parabilis Medicines (PBLS), which priced on June 9 at a deal size of $670 million, is up more than 36% from its offer price. Avalyn Pharma (AVLN), which went public in late April, has posted the strongest return among recent biotech names — up roughly 67% since its offering. Hemab Therapeutics (COAG) has also performed well, gaining around 39% since its April 30 pricing.
On the weaker end, Lakewood Amedex Bio (LABT) has seen its share price collapse roughly 90% since its April 23 debut, which serves as a stark reminder of the risks inherent in early-stage biotech listings. Suja Life (SUJA), a consumer health and juice brand, is down about 50% from its May offering price.
The Technology and Defense Names
Quantinuum (QNT), a quantum computing company that raised $1.68 billion in early June, is trading about 8% below its IPO price — notable given the broader excitement around quantum technology. HawkEye 360 (HAWK), a space-based radio frequency analytics firm with defense applications, is also slightly below its offer price after pricing in early May.
Liftoff Mobile (LFTO), a mobile marketing platform, raised $437 million in early June and is modestly up around 6% since its debut.
Mining and Minerals
The natural resources space has had entries on both ends of the spectrum. WhiteHawk Minerals (WHK), which priced June 8, is up about 5% from its offer price. Silver Bow Mining (SBMT), by contrast, is down more than 23% since its late April debut. Rare Earths Americas (REA) — a timely name given ongoing global interest in critical minerals supply chains — is roughly flat, down just over 3% from its early May pricing.
What the Data Suggests
Looking across the full slate of recent IPOs, a few patterns emerge. Pharma and biotech names have shown the widest variance — some delivering exceptional early gains, others losing the vast majority of their value. Energy transition plays, particularly in geothermal and gas-engine technology, have held up relatively well. And the marquee technology names, while not universally strong out of the gate, continue to draw large deal sizes.
It is worth noting that post-IPO performance in the short term does not necessarily reflect a company's long-term business prospects. Many factors influence early trading, including market timing, institutional allocation, and broader sector sentiment.
The Bigger Picture
The volume and diversity of 2026 IPOs through mid-June suggests that the primary market remains open and reasonably receptive, even if returns are inconsistent. For observers of market structure, the mix of sectors hitting public markets — quantum computing, geothermal energy, space technology, critical minerals — reflects the themes that investors and companies alike are prioritizing heading into the latter half of the decade.
Whether the momentum holds through the rest of the year will depend heavily on macroeconomic conditions, interest rate expectations, and whether early IPO performers can sustain their gains as lock-up periods expire and broader scrutiny sets in.